Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease
Wei‐Ying Jen,Hagop Kantarjian,Tapan M. Kadia,Courtney D. DiNardo,Ghayas C. Issa,Nicholas J. Short,Musa Yilmaz,Gautam Borthakur,Farhad Ravandi,Naval G. Daver
DOI: https://doi.org/10.1111/bjh.19519
2024-05-10
British Journal of Haematology
Abstract:The treatment landscape of acute myeloid leukaemia (AML) is evolving rapidly. However, despite advances in treatment and the approval of an increasing number of novel agents, approximately 50% of AML patients will invariably relapse. We review the data supporting the use of key novel agents in AML, known mechanisms of relapse following these therapies and how they may be optimally combined to improve AML outcomes. Additionally, we present our clinical experience with these combinations and discuss how they are safely utilised. Both AML with mutational targets and mutation agnostic combinations are explored. Summary The treatment landscape of acute myeloid leukaemia (AML) is evolving rapidly. Venetoclax in combination with intensive chemotherapy or doublets or triplets with targeted or immune therapies is the focus of numerous ongoing trials. The development of mutation‐targeted therapies has greatly enhanced the treatment armamentarium, with FLT3 inhibitors and isocitrate dehydrogenase inhibitors improving outcomes in frontline and relapsed/refractory (RR) AML, and menin inhibitors showing efficacy in RR NPM1mut and KMT2A‐rearranged AML. With so many new drugs approved, the number of potential combinatorial approaches to leverage the maximal benefit of these agents has increased dramatically, while at the same time introducing clinical challenges, such as key preclinical and clinical data supporting the development of combinatorial therapy, how to optimally combine or sequence these novel agents, how to optimise dose and duration to maintain safety while enhancing efficacy, the optimal duration of therapy and the role of measurable residual disease in decision‐making in both intensive and low‐intensity therapy settings. In this review, we will outline the evidence leading to the approval of key agents in AML, their on‐label current approvals and how they may be optimally combined in a safe and deliverable fashion to further improve outcomes in AML.
hematology